Delphine Coste‐Zeitoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Delphine Coste‐Zeitoun has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anna Kaminska
APHP, Department of Clinical Neurophysiology, Necker-Enfants Malades Hospital, Paris, France
1 shared publication Emma Losito
Department of Pediatric Neurology, Reference Center for Rare Epilepsies Hôpital Necker‐Enfants Malades, member of ERN EpiCARE Paris France
1 shared publication- Giulia Barcia
Hôpital Necker Enfants Malades
1 shared publication - Isabelle Desguerre
Reference Center for Neuromuscular Disorders Nord/Ile de France/Est, Pediatric Neurology Service, APHP Hospital Necker-Enfants Malades, APHP, Paris, France
1 shared publication - Marie Hully
Department of Pediatric Neurology, Necker Hospital, APHP Centre Paris, France
1 shared publication - Mathieu Kuchenbuch
Department of Pediatrics, Reference Center for Rare Epilepsies, member of the European Reference Network EpiCARE, University Hospital of Nancy, Nancy, France
1 shared publication
Latest Publications
- Open Access
- 18 September 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (9) , e70304
Assessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies
Background: Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis (TSC), with off‐label use in drug‐resistant epilepsies. The aim of this study is to evaluate efficacy, safety, and long‐term retention of CBD in a large pediatric population.Methods: We prospectively included all consecutive patients initiating CBD for drug‐resistant epilepsy at our pediatric tertiary center from 2019 to 2021. Efficacy and safety were assessed via parental questionnaires on seizure and non‐seizure outcomes at 1, 2, and 6 months, comparing each item to prior clinic visits. Retention rate was evaluated at 18 months.Results: We included 103 patients (mean age 11.2 years), with 47% receiving CBD for label‐approved syndromes (23 DS, 15 LGS, 10 TSC) and 53% off‐label. At 1 month, 54% of caregivers reported reduced seizure frequency and duration, with a positive overall impression in 62%. By months 2–6, 48% maintained seizure improvement, alongside sustained gains in communication (60%), alertness (54%), and motor skills (44%). Retention rates were 97% at 1 month, 90% at 2 months, 82% at 6 months, 66% at 12 months, and 55% at 18 months. Off‐label use (p = 0.02), male gender (p = 0.049), and older age at initiation (p = 0.03) were associated with higher retention.Conclusions: CBD reduced seizures and improved non seizures' morbidities in drug‐resistant epilepsy. Strong 18‐month retention rate, including off‐label use, highlights efficacy and tolerability, underscoring the need for further real‐world data in various rare epilepsy syndromes beyond its market approval.
- 18 September 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (9) , e70304
Open AccessAssessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies
Background: Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis (TSC), with off‐label use in drug‐resistant epilepsies. The aim of this study is to evaluate efficacy, safety, and long‐term retention of CBD in a large pediatric population.Methods: We prospectively included all consecutive patients initiating CBD for drug‐resistant epilepsy at our pediatric tertiary center from 2019 to 2021. Efficacy and safety were assessed via parental questionnaires on seizure and non‐seizure outcomes at 1, 2, and 6 months, comparing each item to prior clinic visits. Retention rate was evaluated at 18 months.Results: We included 103 patients (mean age 11.2 years), with 47% receiving CBD for label‐approved syndromes (23 DS, 15 LGS, 10 TSC) and 53% off‐label. At 1 month, 54% of caregivers reported reduced seizure frequency and duration, with a positive overall impression in 62%. By months 2–6, 48% maintained seizure improvement, alongside sustained gains in communication (60%), alertness (54%), and motor skills (44%). Retention rates were 97% at 1 month, 90% at 2 months, 82% at 6 months, 66% at 12 months, and 55% at 18 months. Off‐label use (p = 0.02), male gender (p = 0.049), and older age at initiation (p = 0.03) were associated with higher retention.Conclusions: CBD reduced seizures and improved non seizures' morbidities in drug‐resistant epilepsy. Strong 18‐month retention rate, including off‐label use, highlights efficacy and tolerability, underscoring the need for further real‐world data in various rare epilepsy syndromes beyond its market approval.